CAMP
Camp4 Therapeutics CorpCompany Information
- Company Name
- Camp4 Therapeutics Corp
- CIK
- CIK0001736730
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- CAMP: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CAMP
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-09-11
- Last sale
- —
- Shares purchased (TTM)
- 12,988,879
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 39,751,937
- Shares outstanding
- 57,923,674
- Ownership
- 68.63%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -2.00%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 86 | 99 | 110 | 75 | 39 | 49 | 64 | 3 | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | - | - | 1 | ||||||
| Restricted Cash Current | 1 | 1 | 1 | - | - | - | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 3 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | ||||||
| Assets Current | 90 | 102 | 114 | 78 | 41 | 52 | 66 | 6 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | ||||||
| Deferred Costs | - | - | - | - | - | - | - | 3 | ||||||
| Property Plant And Equipment Net | - | - | - | 3 | 3 | 4 | 4 | - | ||||||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 2 | 2 | 2 | - | - | - | 4 | - | ||||||
| Operating Lease Right Of Use Asset | 1 | 0 | 0 | 4 | 5 | 6 | 6 | 6 | ||||||
| Finance Lease Right Of Use Asset | - | - | - | 0 | 0 | 0 | 0 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Assets | 93 | 105 | 118 | 86 | 51 | 63 | 78 | 21 | ||||||
Liabilities Current | ||||||||||||||
| Accounts Payable Current | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 4 | ||||||
| Accrued Liabilities Current | 4 | 4 | 6 | 4 | 3 | 2 | 5 | 4 | ||||||
| Contract With Customer Liability Current | 13 | 11 | 9 | 0 | 0 | 0 | 0 | 1 | ||||||
| Operating Lease Liability Current | 1 | 0 | 0 | 3 | 3 | 3 | 3 | 3 | ||||||
| Finance Lease Liability Current | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Current | - | - | 0 | - | - | - | 0 | - | ||||||
| Liabilities Current | 19 | 17 | 16 | 8 | 7 | 6 | 10 | 12 | ||||||
Liabilities Noncurrent | ||||||||||||||
| Contract With Customer Liability Noncurrent | 2 | 5 | 8 | - | - | - | 0 | - | ||||||
| Operating Lease Liability Noncurrent | 2 | 2 | 2 | 3 | 4 | 5 | 5 | 6 | ||||||
| Finance Lease Liability Noncurrent | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Derivative Liabilities Noncurrent | 72 | 51 | 45 | 17 | - | - | 0 | - | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 94 | 75 | 70 | 28 | 11 | 11 | 15 | 18 | ||||||
Stockholders Equity | ||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 343 | 341 | 340 | 311 | 277 | 276 | 275 | 39 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | 0 | - | - | - | 0 | 162 | ||||||
| Retained Earnings Accumulated Deficit | -344 | -310 | -292 | -252 | -237 | -224 | -212 | -198 | ||||||
| Stockholders Equity | -1 | 31 | 48 | 59 | 40 | 52 | 63 | -159 | ||||||
| Liabilities And Stockholders Equity | 93 | 105 | 118 | 86 | 51 | 63 | 78 | 21 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 175 | 175 | 175 | 175 | 175 | 175 | 175 | 175 | ||||||
| Common Stock Shares Issued | 52 | 52 | 52 | 47 | 20 | 20 | 20 | 1 | ||||||
| Shares Outstanding | 52 | 52 | 52 | 47 | 20 | 20 | 20 | 1 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | 0.00 | 0.00 | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | 25 | 150 | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | 0 | 131 | ||||||
| Temporary Equity Shares Outstanding | - | - | 0 | - | - | - | 0 | 131 | ||||||
| Temporary Equity Liquidation Preference | - | - | - | - | - | - | 0 | 163 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCamp4 Therapeutics Corp (CAMP) — SEC Financial Statements & Analysis
Camp4 Therapeutics Corp (CAMP) is a pharmaceutical preparations company, incorporated in DE. Camp4 Therapeutics Corp trades on Nasdaq as: CAMP. Camp4 Therapeutics Corp (CAMP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Camp4 Therapeutics Corp carries a market cap of $253.15M, a P/E ratio of -2.36x, a P/B ratio of -365.30x, a P/S ratio of 60.05x, an enterprise value of $165.13M, and an EV/EBITDA multiple of -3.23x. On profitability, it posts an operating margin of -1254.22%, a net margin of -2543.74%, a Return on Equity (ROE) of -545.85%, and a Return on Assets (ROA) of -148.23%. Per share, it reports EPS of $-1.85, diluted EPS of $-1.85, free cash flow per share of $-0.50, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 40.21% year-over-year, net income growth of 39.62% year-over-year, and EPS growth of -51.41% year-over-year. On the balance sheet, it maintains a current ratio of 4.70x, a quick ratio of 4.55x, working capital of $70.89M, a debt-to-equity ratio of -135.82x, a debt ratio of 1.01, free cash flow of $-28.72M (TTM), and net debt of $-88.02M. Figures sourced from SEC EDGAR.
- Market Cap
- $253.15M
- P/E TTM
- -2.36x
- EPS TTM
- $-1.85
- P/B TTM
- -365.30x
- ROE TTM
- -545.85%
- ROA TTM
- -148.23%
- Debt To Equity
- -135.82x
- Free Cash Flow TTM
- $-28.72M
- Net Revenue TTM Growth 1Y
- 40.21%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Camp4 Therapeutics Corp in?
Camp4 Therapeutics Corp (CAMP) operates in the Pharmaceutical Preparations industry.
What exchange does CAMP trade on?
Camp4 Therapeutics Corp (CAMP) trades on the Nasdaq.
Where is Camp4 Therapeutics Corp incorporated?
Camp4 Therapeutics Corp is incorporated in DE.
When was Camp4 Therapeutics Corp (CAMP)'s most recent SEC filing?
Camp4 Therapeutics Corp (CAMP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is CAMP's market cap?
Camp4 Therapeutics Corp (CAMP) has a market capitalization of $253.15M as of 2026-06-30.
What is CAMP's EPS (earnings per share)?
Camp4 Therapeutics Corp (CAMP)'s trailing twelve month EPS is $-1.85 as of 2026-06-30.
What is CAMP's ROE (return on equity)?
Camp4 Therapeutics Corp (CAMP)'s trailing twelve month Return on Equity (ROE) is -545.85% as of 2026-06-30.
What is CAMP's ROA (return on assets)?
Camp4 Therapeutics Corp (CAMP)'s trailing twelve month Return on Assets (ROA) is -148.23% as of 2026-06-30.
What is CAMP's EV/EBITDA?
Camp4 Therapeutics Corp (CAMP)'s trailing twelve month EV/EBITDA is -3.23x as of 2026-06-30.